EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Haixiang Zheng, Leonardo Antonio Sechi, Eliano Pio Navarese, Gavino Casu, Gianpaolo Vidili

Cardiovascular Diabetology · 28.09.2024 · 23 (1)

DOI: 10.1186/s12933-024-02434-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Diabetology, online erschienen am 28.09.2024. Verfasst von Haixiang Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of Sassari, 07100, Sassari, Italy. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Cardiovascular Diseases, Heart Disease Risk Factors. Die Arbeit wurde bisher 207-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), poses a significant global health challenge due to its increasing prevalence and strong association with cardiovascular disease (CVD). This comprehensive review summarizes the current knowledge on the MASLD-CVD relationship, compares analysis of how different terminologies for fatty liver disease affect cardiovascular (CV) risk assessment using different diagnostic criteria, explores the pathophysiological mechanisms connecting MASLD to CVD, the influence of MASLD on traditional CV risk factors, the role of noninvasive imaging techniques and biomarkers in the assessment of CV risk in patients with MASLD, and the implications for clinical management and prevention strategies. By incorporating current research and clinical guidelines, this review provides a comprehensive overview of the complex interplay between MASLD and cardiovascular health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseCardiovascular DiseasesHeart Disease Risk FactorsHumansRisk AssessmentPrognosisPrevalenceRisk FactorsBiomarkers

Stichwörter der Autor:innen

Cardiovascular riskMetabolic dysfunction-associated steatotic liver diseaseMetabolic-associated fatty liver diseaseNonalcoholic fatty liver disease

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Biomedical Sciences, University of Sassari, 07100, Sassari, Italy.
  • Department of Cardiology, The Second Affiliated Hospital of Shantou University Medical College, 515041, Shantou, China.
  • Complex Structure of Microbiology and Virology, AOU Sassari, 07100, Sassari, Italy.
  • Clinical and Experimental Cardiology, Clinical and Interventional Cardiology, University of Sassari, Sassari, Italy.
  • Department of Medicine, Surgery, and Pharmacy, University of Sassari, Azienda Ospedaliero, 07100, Sassari, Italy. gvidili@uniss.it.

Zitieren

APA

Zheng, H., Sechi, L. A., Navarese, E. P., Casu, G., & Vidili, G. (2024). Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovascular Diabetology, 23(1). https://doi.org/10.1186/s12933-024-02434-5

Vancouver

Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovascular Diabetology. 2024;23(1). doi:10.1186/s12933-024-02434-5

BibTeX
@article{Zheng2024,
  author = {Zheng, Haixiang and Sechi, Leonardo Antonio and Navarese, Eliano Pio and Casu, Gavino and Vidili, Gianpaolo},
  title = {Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review},
  journal = {Cardiovascular Diabetology},
  year = {2024},
  volume = {23},
  number = {1},
  doi = {10.1186/s12933-024-02434-5}
}
Kostenlos starten →